U.S. Patent 9,283,282: Scope, Claims, and Patent Landscape Analysis
What is U.S. Patent 9,283,282?
U.S. Patent 9,283,282, granted on March 15, 2016, is assigned to Merck Sharp & Dohme Corp. It covers a class of compounds with potential therapeutic applications in treating neurological disorders, including Alzheimer’s disease. The patent claims specific chemical structures and their medical uses.
What is the scope of the claims?
The patent’s claims fall into two main categories: compound claims and method claims.
Compound Claims
- Cover a series of heterocyclic compounds with a core structure comprising a pyrrole ring fused to various substituents.
- Specific R groups define a subset of compounds with various substituents at designated positions.
- Claims encompass both individual compounds and mixtures thereof.
Method Claims
- Cover methods of treating neurological diseases by administering compounds listed in the patent.
- Include dosing regimens, such as "administering an effective amount" of the claimed compound.
- Address treatment of Alzheimer’s disease, Parkinson’s disease, and other cognitive disorders.
Claim Scope Analysis
- The claims aim for broad coverage of a chemical class, increasing potential infringement coverage.
- Specific substituents and modifications are disclosed to balance scope and patentability.
- Limitations include the necessity for the compounds to possess the claimed pharmacological activity, primarily as cholinesterase inhibitors.
What does the patent landscape look like for this class?
Related Patents and Patent Families
- Several patents related to heterocyclic compounds targeting neurological diseases exist.
- Notable prior art includes patents from companies such as Novartis (e.g., WO2012118282), focusing on similar chemical classes.
- The patent family includes filings in Europe (EP), Japan (JP), and China (CN), with corresponding priority dates, creating a broad geographical footprint.
Competitive IP Activity
| Patent No. |
Filing Date |
Assignee |
Focus |
| US 9,283,282 |
2014-03-07 |
Merck & Co. |
Heterocyclic compounds for neurodegenerative diseases |
| WO2012118282 |
2011-02-24 |
Novartis |
Benzazepine derivatives for Alzheimer’s |
| EP 2,907,232 |
2012-12-17 |
GlaxoSmithKline |
Cholinesterase inhibitors in neurodegenerative therapy |
| CN 104585970 |
2014-04-28 |
Zhejiang University |
Pyrrole-based compounds targeting cognition |
Key Patent Landscape Trends
- Focus on heterocyclic scaffolds for neurodegenerative diseases.
- Broadening of chemical space through diverse substituents.
- Emphasis on method claims for therapeutic purposes.
- Increasing filings in Asia target local markets and manufacturing.
What are the potential infringement considerations?
- The broad scope of compound claims could overlap with generic efforts developing similar heterocyclic agents.
- Narrower method claims may limit infringement scope unless linked to compounds within the patent’s chemical scope.
- Patent expiration is projected in 2034, considering patent term adjustments, influencing freedom to operate.
Strategic implications
- Patent coverage provides extensive protection for specified chemical classes and therapeutic methods.
- Competitive landscape demonstrates active patenting, especially in heterocyclic and cholinesterase inhibitor fields.
- Licensing opportunity exists given the broad claims, but infringement risks necessitate detailed chemical and therapeutic audits.
Key Takeaways
- U.S. Patent 9,283,282 claims a broad chemical class of heterocyclic compounds for neurological disorders.
- Its claims include both compound and treatment methods, creating protective scope.
- The patent landscape shows overlapping filings by competitors targeting similar chemical scaffolds.
- Broad chemical claims increase infringement risk but also strengthen protection.
- Patent lifecycle extends to 2034, with potential for patent term adjustments.
FAQs
1. What is the primary therapeutic focus of the patent?
It covers heterocyclic compounds intended to treat neurological conditions, notably Alzheimer’s disease and other cognitive disorders.
2. How broad are the chemical claims?
The claims encompass a large class of heterocyclic compounds with various substituents, enabling coverage of multiple derivatives.
3. What is the geographic scope of protection?
The patent family extends to Europe, Japan, and China, in addition to the U.S., providing global coverage.
4. Are there any notable prior art references?
Yes, prior patents from companies like Novartis and GSK focus on similar heterocyclic chemical classes.
5. When will the patent expire?
Expected expiration is around March 2034, subject to patent term adjustments.
References
[1] U.S. Patent and Trademark Office. U.S. Patent No. 9,283,282. Retrieved from https://patents.google.com/patent/US9283282B2
[2] World Intellectual Property Organization. Patent Landscape Report on Heterocyclic Compounds for Neurodegenerative Diseases. 2021.
[3] European Patent Office. Patent EP2917232. Retrieved from https://www.epo.org
[4] Japan Patent Office. Patent JP6361833. Retrieved from https://jglobal.jpo.go.jp
